Orexigen Therapeutics, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 76   

Articles published

OREX 5.67 +0.11 (1.98%)
price chart
Contrave Scripts Continue Increases For Orexigen
At this time Orexigen maintains all rights outside North America. Once approved for Europe, Orexigen will have a valuable commodity for a big pharma company to latch on to. Takeda is Orexigen's partner in North America, and would be a likely front ...
Why Orexigen Therapeutics, Inc. Stock Skyrocketed
What: Shares of Orexigen Therapeutics (NASDAQ: OREX ) , a biopharmaceutical company focused on developing therapies to treat obesity, surged higher by as much as 33% after the company reported its third-quarter earnings results and provided an ...
Orexigen Beats The Street On Milestone Payments (OREX)  Seeking Alpha (registration)
Orexigen Therapeutics rises as European Union review of weight loss drug ...  Fox Business
Related articles »  
How Bad Is This Delay for Orexigen Therapeutics, Inc?
Orexigen Therapeutics (NASDAQ: OREX ) recently announced that the Food and Drug Administration was delaying an approval decision on the biotech's obesity drug Contrave for three months.
Why Orexigen Therapeutics, Inc. Stock Rocketed 43% Higher in November
What: Shares of Orexigen Therapeutics (NASDAQ: OREX ) , a biopharmaceutical company focused on developing drugs to treat obesity, put on some serious heft and gained 43% during the month of November, data courtesy of S&P Capital IQ, after reporting ...
Rocketed profits of Orexigen (NASDAQ:OREX) Therapeutics  WallStreet.org
Earnings Estimates Moving Higher for Orexigen (OREX): Time to Buy?  Zacks.com
Related articles »  
FDA Approves Orexigen Therapeutics Inc.'s Goldilocks Obesity Drug
In 2011, Orexigen was in a tight race with VIVUS (NASDAQ: VVUS ) and Arena Pharmaceuticals (NASDAQ: ARNA ) to gain FDA approval of the first new obesity drug.
Orexigen Wins US FDA Approval for Weight-Loss Pill  Businessweek
Takeda and Orexigen Announce FDA Approval of Contrave´┐Ż (naltrexone HCI ...  MarketWatch
Related articles »  
Stock Update: Orexigen Therapeutics Inc. (NASDAQ:OREX)
Orexigen Therapeutics, Inc. (NASDAQ:OREX) is currently trading 33.12% below its 52-week-high, 68.17% above its 52-week-low.
First Call Rating Update on Orexigen Therapeutics, Inc.
Orexigen Therapeutics, Inc. (NASDAQ:OREX): First Call has given a rating of Buy to Orexigen Therapeutics, Inc., according to the consensus released by the firm. Analysts from various Brokerage Firms have rated the company and commented on its price ...
Will Standard Pacific Corp.(SPF), Orexigen Therapeutics, Inc.(OREX) and ...  GSPInsider
Stocks Underperform for the Week: Orexigen Therapeutics Inc , Kimberly-Clark ...  Ashburn Daily
Not Even a Weight Loss Drug Could Stop Orexigen Therapeutics, Inc. From ...
Those fears have sparked a flurry of research and development into drugs that could help reduce the risk of type 2 diabetes by helping patients lose weight, including Orexigen Therapeutics' (NASDAQ: OREX ) recently approved Contrave. Yet despite ...
Related articles »  
BUZZ-Orexigen Therapeutics Inc: Diet drug launched
Contrave, which was approved last month, competes with Vivus Inc's Qsymia and Arena Pharmaceutical Inc's Belviq.
Stock Insight: Orexigen Therapeutics Inc. (NASDAQ:OREX)
[PRNewswire] Orexigen Therapeutics, Inc. (NASDAQ:OREX) (TREND ANALYSIS) announced that the Committee for Medicinal Products For Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the ...
Orexigen Therapeutics PT Set at $10.00 by Bank of America (OREX)  WKRB News
Brokerage Firm Issues Rating: Orexigen Therapeutics, Inc. , OReilly ...  Stafford Daily
Related articles »